This is an interesting article for HN. It's spun as a negative, using terms like "threatening", "monopoly", "controversial", and "retribution". You could write it the other way, where an immigrant-founded[1] startup is disrupting the mental health industry. Frankly, most of this seems like par for the course. Of course the company is seeking to push their product to market and commercial viability--and the potential…
did you read the article completely? there are 9 critics that worked with them, 6 ceased doing so. the company formed and closed it's non-profit venture and they are using typical pharma tactics, creating patents around it. spin is one thing but those facts do tell a story on it's own. > These experts are further troubled by the company’s business structure: Having first registered as a charity, Goldsmith and Malievs…
To me, there's an undercurrent here that some of the psychedelic experts have specific, subjective viewpoints (à la Richard Stallman). That these people have concerns is interesting, but the case that they're material or even right wasn't proven.
Again, no surprise that they shuttered the nonprofit: it's a corporate structure that precludes you from raising traditional VC, among other limitations. And since they are now a competitive pharmaceutical company, is it any surprise that they're using... competitive pharmaceutical tactics? And, again, is that material? Or is it just tsk-tsk'ing "the way things ought to be"?
These things do tell a very interesting story about pharma practices, research, start-up risks, a subculture going mainstream, etc. I think that story can be told more clearly.